Research Guide
GLP-1 and related incretin-pathway peptides represent one of the fastest-growing categories in current research, driven by the metabolic and weight-management research surrounding them. This guide breaks down the category, how compounds within it differ, and where to go deeper.
Quick summary
- GLP-1 refers to a receptor pathway, not a single compound — multiple peptides act on it in different ways.
- Newer compounds add activity at additional receptors (GIP, glucagon) beyond GLP-1 alone.
- Receptor scope is the main variable that distinguishes one compound from another in this category.
- Retatrutide is currently the most advanced multi-receptor compound in our catalog.
What the GLP-1 pathway actually is
GLP-1, or glucagon-like peptide-1, is a naturally occurring incretin hormone involved in regulating insulin secretion, gastric emptying, and appetite signaling. “GLP-1 peptide” is often used as shorthand for any compound that activates this receptor, but it is a pathway, not a single molecule, and research compounds vary widely in how selectively or broadly they act on it.
Single-receptor vs. multi-receptor compounds
The earliest generation of research compounds in this space acted on the GLP-1 receptor alone. More recent research has moved toward multi-receptor agonists, compounds engineered to activate GLP-1 alongside one or more additional receptors, most commonly GIP and, in newer compounds, glucagon. The research premise is that stacking receptor activity produces effects beyond what any single pathway achieves on its own, though this is still an active area of study rather than settled science.
Retatrutide: a triple-receptor compound
Retatrutide is the most advanced multi-receptor compound in our catalog, studied for simultaneous activity at the GLP-1, GIP, and glucagon receptors. Its glucagon receptor activity is what sets it apart from most earlier compounds in this category, since glucagon is typically associated with raising blood sugar rather than the metabolic effects under study here.
Read our full Retatrutide breakdown →
What to look for when comparing compounds in this category
- Which receptors the compound is studied to act on (GLP-1 only, or GLP-1 plus GIP and/or glucagon)
- How mature the published research base is (preclinical only, or through human clinical trials)
- Whether the compound has an approved pharmaceutical analog, which typically means a larger published safety dataset
- Third-party purity verification for the specific lot you are researching with
Frequently asked questions
Is GLP-1 a specific peptide or a category?
GLP-1 refers to a receptor pathway. Multiple distinct peptides are studied for their activity on that pathway, either alone or alongside other receptors.
Are multi-receptor compounds always more effective than single-receptor ones?
This is still an active research question. Multi-receptor compounds are of research interest specifically because it is not yet fully established whether stacking receptor activity produces proportionally greater effects.
Look up a Certificate of Analysis →
For laboratory and research use only. Not for human consumption. This article is for informational purposes; it is not medical advice.
